Please use a PC Browser to access Register-Tadawul
BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI
Polyrizon Ltd. -3.67%
Clearmind Medicine Inc. +5.56%
Polyrizon Ltd. PLRZ | 13.11 | -3.67% |
Clearmind Medicine Inc. CMND | 1.14 | +5.56% |
Feb 6 (Reuters) - Clearmind Medicine Inc CMND.O:
CLEARMIND MEDICINE ENTERS INTO DEVELOPMENT AGREEMENT TO ADVANCE INTRANASAL FORMULATION FOR ITS PROPRIETARY NON-HALLUCINOGENIC NEUROPLASTOGEN MEAI
Source text: ID:nGNX8L1NC0
Further company coverage: CMND.O


